1. Modeling the population health benefits of LDL-C reduction with alirocumab among cardiovascular disease/heterozygous familial hypercholesterolemia patients with elevated LDL-C. (August 2018) Authors: Sanchez, R.; Nasir, K.; Klimchak, A.; Kuznik, A.; Joulain, F.; Briggs, A. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗